191 related articles for article (PubMed ID: 38348048)
21. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
22. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
23. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
24. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
Apollonio B; Spada F; Petrov N; Cozzetto D; Papazoglou D; Jarvis P; Kannambath S; Terranova-Barberio M; Amini RM; Enblad G; Graham C; Benjamin R; Phillips E; Ellis R; Nuamah R; Saqi M; Calado DP; Rosenquist R; Sutton LA; Salisbury J; Zacharioudakis G; Vardi A; Hagner PR; Gandhi AK; Bacac M; Claus C; Umana P; Jarrett RF; Klein C; Deutsch A; Ramsay AG
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37219943
[TBL] [Abstract][Full Text] [Related]
25. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
26. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
27. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L; García-Domínguez DJ; Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Sánchez-León ML; Silva-Romeiro S; Flores-Campos R; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; Provencio-Pulla M; Sánchez-Beato M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Rueda-Domínguez A; Sánchez-Margalet V; de la Cruz-Merino L
Front Immunol; 2024; 15():1293931. PubMed ID: 38469299
[TBL] [Abstract][Full Text] [Related]
28. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of circulating neutrophils and lymphocyte subsets in newly diagnosed patients with diffuse large B-cell lymphoma.
Yang Z; Yu W
Clin Exp Med; 2023 Jul; 23(3):815-822. PubMed ID: 35939174
[TBL] [Abstract][Full Text] [Related]
30. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
[TBL] [Abstract][Full Text] [Related]
31. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV; Duetz C; Bruins WSC; Korst CLBM; Rentenaar R; Cosovic M; Eken M; Twickler I; Nijland M; van der Poel MWM; de Heer K; Klerk CPW; Strobbe L; Oosterveld M; Boersma R; Koene HR; Roemer MGM; van Werkhoven E; Chamuleau MED; Mutis T
Blood Adv; 2024 Mar; 8(5):1094-1104. PubMed ID: 38191686
[TBL] [Abstract][Full Text] [Related]
32. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract][Full Text] [Related]
33. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
34. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
[TBL] [Abstract][Full Text] [Related]
35. High levels of Tim-3
Zhong W; Liu X; Zhu Z; Li Q; Li K
Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
[TBL] [Abstract][Full Text] [Related]
36. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
Ansell SM; Stenson M; Habermann TM; Jelinek DF; Witzig TE
J Clin Oncol; 2001 Feb; 19(3):720-6. PubMed ID: 11157023
[TBL] [Abstract][Full Text] [Related]
37. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
Plonquet A; Haioun C; Jais JP; Debard AL; Salles G; Bene MC; Feugier P; Rabian C; Casasnovas O; Labalette M; Kuhlein E; Farcet JP; Emile JF; Gisselbrecht C; Delfau-Larue MH;
Ann Oncol; 2007 Jul; 18(7):1209-15. PubMed ID: 17496307
[TBL] [Abstract][Full Text] [Related]
38. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
39. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
40. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
Hasselblom S; Sigurdadottir M; Hansson U; Nilsson-Ehle H; Ridell B; Andersson PO
Br J Haematol; 2007 May; 137(4):364-73. PubMed ID: 17456059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
